Globale Studie, die eine Rivaroxaban-basierte antithrombotische Strategie vergleicht mit einer auf Plättchenhemmern basierenden Strategie bei Patienten nach Transkatheter-Aortenklappenimplantation (TAVI), dies mit dem Ziel, das Ergebnis zu verbessern.

Drug: Rivaroxaban (Xarelto, BAY59-7939);Drug: Acetylsalicylic Acid (ASA);Drug: Clopidogrel;Drug: Vitamin K antagonist (VKA)

Inclusion Criteria:

- Successful TAVR (Transcatheter Aortic Valve Replacement) of an aortic valve stenosis
(either native or valve-in-valve)

- By iliofemoral or subclavian access

- With any approved/marketed device

Exclusion Criteria:

- Atrial fibrillation (AF), current or previous, with an ongoing indication for oral
anticoagulant treatment

- Any other indication for continued treatment with any oral anticoagulant (OAC)

- Known bleeding diathesis (such as but not limited to active internal bleeding,
clinically significant bleeding, platelet count = 50,000/mm3 at screening, hemoglobin
level < 8.5 g/dL, active peptic ulcer or known gastrointestinal (GI) bleeding, history
of intracranial hemorrhage or subdural hematoma)

- Any ongoing absolute indication for dual antiplatelet therapy (DAPT) at time of
screening that is unrelated to the TAVR procedure

- Clinically overt stroke within the last 3 months

- Planned coronary or vascular intervention or major surgery

- Severe renal impairment (eGFR < 30 mL/min/1.73 m2) or on dialysis, or post-TAVR
unresolved acute kidney injury with renal dysfunction stage 2 or higher

- Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic
disease associated with coagulopathy